Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andy C Rawstron

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Best Practice & Research. Clinical Haematology|August 21, 2007
Minimal residual disease assessment in chronic lymphocytic leukaemiaHazem A Sayala, Andy C Rawstron, Peter Hillmen
Cytometry. Part B, Clinical Cytometry|July 24, 2015
Assessment of minimal residual disease in myeloma and the need for a consensus approachAndy C Rawstron, Bruno Paiva, Maryalice Stetler-Stevenson
Clinical Lymphoma|March 30, 2005
CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessmentRoger G Owen, Peter Hillmen, Andy C Rawstron
Current Hematologic Malignancy Reports|April 29, 2010
Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment?Abraham M Varghese, Andy C Rawstron, Peter Hillmen
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2013
Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cellsRuth M de Tute, Andy C Rawstron, Roger G Owen
Cancer Genetics and Cytogenetics|October 11, 2005
IgM myeloma with t(4;14)(p16;q32)Sam Ackroyd, Sheila J O'Connor, Andy C Rawstron, et al.
Cytometry. Part B, Clinical Cytometry|July 7, 2015
Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic ServiceAndy C Rawstron, Ruth M de Tute, J Haughton, et al.
Blood|June 4, 2005
The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cellsMona H Al Rayes, Andy C Rawstron, Gareth J Morgan, et al.
Blood|June 19, 2014
Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysisQuentin A Hill, Andy C Rawstron, Ruth M de Tute, et al.
British Journal of Haematology|October 1, 2010
Extramedullary plasmacytoma are characterized by a 'myeloma-like' immunophenotype and genotype and occult bone marrow involvementMaayke Boll, Elizabeth Parkins, Sheila J M O'Connor, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Best Practice & Research. Clinical Haematology|August 21, 2007
Minimal residual disease assessment in chronic lymphocytic leukaemiaHazem A Sayala, Andy C Rawstron, Peter Hillmen
Cytometry. Part B, Clinical Cytometry|July 24, 2015
Assessment of minimal residual disease in myeloma and the need for a consensus approachAndy C Rawstron, Bruno Paiva, Maryalice Stetler-Stevenson
Clinical Lymphoma|March 30, 2005
CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessmentRoger G Owen, Peter Hillmen, Andy C Rawstron
Current Hematologic Malignancy Reports|April 29, 2010
Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment?Abraham M Varghese, Andy C Rawstron, Peter Hillmen
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2013
Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cellsRuth M de Tute, Andy C Rawstron, Roger G Owen
Cancer Genetics and Cytogenetics|October 11, 2005
IgM myeloma with t(4;14)(p16;q32)Sam Ackroyd, Sheila J O'Connor, Andy C Rawstron, et al.
Cytometry. Part B, Clinical Cytometry|July 7, 2015
Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic ServiceAndy C Rawstron, Ruth M de Tute, J Haughton, et al.
Blood|June 4, 2005
The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cellsMona H Al Rayes, Andy C Rawstron, Gareth J Morgan, et al.
Blood|June 19, 2014
Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysisQuentin A Hill, Andy C Rawstron, Ruth M de Tute, et al.
British Journal of Haematology|October 1, 2010
Extramedullary plasmacytoma are characterized by a 'myeloma-like' immunophenotype and genotype and occult bone marrow involvementMaayke Boll, Elizabeth Parkins, Sheila J M O'Connor, et al.
Pageof 8